

Resource Summary Report

Generated by [NIF](#) on Aug 26, 2026

MDA-MB-468

RRID:CVCL_0419

Type: Cell Line

Proper Citation

RRID:CVCL_0419

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0419

Proper Citation: RRID:CVCL_0419

Description: Cell line MDA-MB-468 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: [PMID:730202](#), [PMID:1961733](#), [PMID:3518877](#), [PMID:9671407](#), [PMID:10969801](#), [PMID:11414198](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:15153330](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:18262045](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:21778573](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:23856246](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24279929](#), [PMID:25485619](#), [PMID:25699542](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:29273624](#), [PMID:30613774](#), [PMID:30787054](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32576280](#), [PMID:34703030](#), [PMID:35839778](#), [PMID:38861359](#), [PMID:40300663](#)

Comments: Population: African American., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-468

Synonyms: MDA-MB 468, MDA-MB468, MDAMB468, MDA-468, MDA468, MB468, MD Anderson-Metastatic Breast-468

Cross References: BTO:BTO_0001570, CLO:CLO_0007641, EFO:EFO_0001216, MCCL:MCC:0000316, CLDB:cl4973, AddexBio:C0006003/4673, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-6647, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-132, BCRJ:0166, BioGRID_ORCS_Cell_line:551, BioSample:SAMN03473056, BioSample:SAMN05292454, BioSample:SAMN10988340, cancercellines:CVCL_0419, CCRID:1101HUM-PUMC000249, CCRID:3101HUMTCHu136, Cell_Model_Passport:SIDM00628, ChEMBL-Cells:ChEMBL3308424, ChEMBL-Targets:ChEMBL614335, CLS:300279, Cosmic:809241, Cosmic:850823, Cosmic:871149, Cosmic:877448, Cosmic:897427, Cosmic:904384, Cosmic:908123, Cosmic:923061, Cosmic:934530, Cosmic:949192, Cosmic:991327, Cosmic:997921, Cosmic:1000125, Cosmic:1010920, Cosmic:1017167, Cosmic:1018467, Cosmic:1044224, Cosmic:1046929, Cosmic:1047691, Cosmic:1136363, Cosmic:1152526, Cosmic:1176635, Cosmic:1287918, Cosmic:1289402, Cosmic:1305384, Cosmic:1309004, Cosmic:1477427, Cosmic:1523775, Cosmic:1524344, Cosmic:1571795, Cosmic:1603223, Cosmic:1609465, Cosmic:1998490, Cosmic:2009514, Cosmic:2036673, Cosmic:2164999, Cosmic:2301533, Cosmic:2318380, Cosmic:2361357, Cosmic:2668276, Cosmic-CLP:908123, DepMap:ACH-000849, DSMZ:ACC-738, DSMZCellDive:ACC-738, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908123, GEO:GSE184543, GEO:GSM75169, GEO:GSM185095, GEO:GSM185096, GEO:GSM217591, GEO:GSM219929, GEO:GSM344356, GEO:GSM344406, GEO:GSM350502, GEO:GSM388214, GEO:GSM421880, GEO:GSM459714, GEO:GSM459722, GEO:GSM466357, GEO:GSM783955, GEO:GSM847418, GEO:GSM847497, GEO:GSM887301, GEO:GSM888376, GEO:GSM1008911, GEO:GSM1053727, GEO:GSM1172984, GEO:GSM1214565, GEO:GSM1238123, GEO:GSM1374663, GEO:GSM1374664, GEO:GSM1374665, GEO:GSM1401650, GEO:GSM1556177, GEO:GSM1556178, GEO:GSM1556179, GEO:GSM1556180, GEO:GSM1556181, GEO:GSM1661984, GEO:GSM1670087, GEO:GSM1833629, GEO:GSM2124671, GEO:GSM2258884, GEO:GSM2258885, GEO:GSM2258886, GEO:GSM2258887, GEO:GSM2258888, GEO:GSM2258889, GEO:GSM2258890, GEO:GSM2258891, GEO:GSM2258892, GEO:GSM2258893, GEO:GSM2258894, GEO:GSM2258895, GEO:GSM2258896, GEO:GSM2258897, GEO:GSM2258898, GEO:GSM2258899, GEO:GSM2258900, GEO:GSM2258901, GEO:GSM2258941, GEO:GSM2258942, GEO:GSM2258943, IARC_TP53:94, IBRC:C10095, ICLC:HTL99024, KCB:KCB 2011114YJ, LiGeA:CCLE_336, LINCS_HMS:50335, LINCS_LDP:LCL-1471, Lonza:809, NCBI_Iran:C208, NCI-DTP:MDA-MB-468, PharmacDB:MDAMB468_907_2019, PRIDE:PXD001680, PRIDE:PXD005295, PRIDE:PXD008222, PRIDE:PXD022325, PRIDE:PXD030304, Progenetix:CVCL_0419, PubChem_Cell_line:CVCL_0419, SLKBase:3578, TOKU-E:2401, TOKU-E:3604, Ubigen:YC-D009, Wikidata:Q16880225

ID: CVCL_0419

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260815T234602+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-468.

No alerts have been found for MDA-MB-468.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3971 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Du Y, et al. (2026) NUSAP1 Recruits DAXX to Suppress HIF-Driven Triple-Negative Breast Cancer Progression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(5), e13380.

Ohashi T, et al. (2026) ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer. *Cancer research communications*, 6(2), 421.

Zhang Y, et al. (2026) Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. *eLife*, 13.

Ochdrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. *Nature communications*, 17(1), 759.

MacLean MR, et al. (2026) Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs. *iScience*, 29(3), 114863.

Kano M, et al. (2026) Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer. *BMC cancer*, 26(1).

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. *iScience*, 29(7), 116390.

Kumi J, et al. (2026) In Vitro Cytotoxicity Assessment of Leaves of *Tieghemella heckelii* on Breast (MDA-MB-468), Liver (HepG2), and Prostate (PC3) Cancer Cell Lines. *BioMed research international*, 2026(1), e2002140.

Sun Y, et al. (2026) CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. *Molecular cancer*, 25(1).

He G, et al. (2026) Vesicle trafficking 1 in breast cancer tissue and serum orchestrates metastatic progression and an immunosuppressive microenvironment. *International immunopharmacology*, 178, 116564.

Umar SM, et al. (2026) β -Catenin-Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939. *Technology in cancer research & treatment*, 25, 15330338261425407.

Yao Y, et al. (2026) Identification and validation of a seven-gene metastasis-associated prognostic model in breast cancer. *Frontiers in genetics*, 17, 1770418.

Grafals-Ruiz N, et al. (2026) M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer. *Molecular cancer therapeutics*.

Ranganathan S, et al. (2026) Gasdermin D Cleavage and Cytokine Release, Indicative of Pyroptotic Cell Death, Induced by Ophiobolin A in Breast Cancer Cell Lines. *International journal of molecular sciences*, 27(2).

Hachey JS, et al. (2026) Exploring the $^{89}\text{Zr}/^{177}\text{Lu}$ Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(7), 1337.

Kopiasz RJ, et al. (2026) Modular Supramolecular Polycations Enable Efficient Delivery of Diverse RNA Therapeutics and Vaccines. *Advanced materials (Deerfield Beach, Fla.)*, 38(16), e13315.

Dang X, et al. (2026) Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform. *Angewandte Chemie (International ed. in English)*, e3286230.

Lin W, et al. (2026) FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. *Cancer immunology research*, 14(2), 335.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Tikum AF, et al. (2026) ^{225}Ac -labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer. *Breast cancer research : BCR*, 28(1), 44.